Golimumab ELISA Kit (Simponi®) (ab237646)
Key features and details
- Sensitivity: 100 ng/ml
- Range: 100 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Golimumab ELISA Kit (Simponi®)
See all Golimumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15% -
Sample type
Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
100 ng/ml -
Range
100 ng/ml - 3000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Golimumab ELISA Kit (Simponi®) (ab237646) is a highly specific and sensitive kit designed for the in vitro determination of Golimumab in biological matrices such as human serum and plasma. The density of color is proportional to the amount of Golimumab captured from the samples and can be quantified when compared with standard curve.
Golimumab (Simponi®) is a human immunoglobulin G1κ monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-α (TNFα). In 2009, it was approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adult patients. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF.
-
Platform
Microplate (12 x 8 well strips)
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Micro ELISA Plate 1 unit Golimumab Standard S1 1 x 0.25ml Golimumab Standard S2 1 x 0.25ml Golimumab Standard S3 1 x 0.25ml Golimumab Standard S4 1 x 0.25ml Golimumab Standard S5 1 x 0.25ml Golimumab Standard S6 1 x 0.25ml Golimumab Standard S7 1 x 0.25ml Assay Buffer 1 x 50ml HRP-conjugate Probe 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 units -
Relevance
Golimumab (Simponi®) is a human immunoglobulin G1? monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-a (TNFa). In 2009, it was approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adult patients. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF. -
Alternative names
- Simponi
- tumor necrosis factor-a
Images
-
Example of Golimumab standard curve
This standard curve is for demonstration only. A standard curve must be run with each assay.
References (0)
ab237646 has not yet been referenced specifically in any publications.
